TABLE 2.
ACR Response Rates at 6 Months
| Product | Monotherapy | Combination Therapy | ||||||
| ACR20 (%) | ACR50 (%) | ACR70 (%) | Source | ACR20 (%) | ACR50 (%) | ACR70 (%) | Source | |
| MTX-IR Patients | ||||||||
| Tofacitinib | 69.0 | 42.0 | 22.0 | Fleischmann et al. 201214 | 50.0 | 32.0 | 14.0 | Van der Heijde et al. 201318 |
| Adalimumab | 46.0 | 22.0 | 12.0 | Van de Putte et al. 200423 | 63.3 | 39.1 | 20.8 | Keystone et al. 200424 |
| Etanercept | 59.0 | 41.0 | 15.0 | Moreland et al. 199925 | 71.0 | 39.0 | 15.0 | Weinblatt et al. 199926 |
| Certolizumab | 46.0 | 23.0 | 6.0 | Fleischmann et al. 200927 | 59.0 | 37.0 | 21.0 | Keystone et al. 200828 |
| Tocilizumab | 70.0 | 40.0 | 25.0 | Dougados et al. 201329 | 51.0 | 25.0 | 11.0 | Kremer et al. 201130 |
| Rituximab | N/A | N/A | N/A | N/A | 51.0 | 27.0 | 12.0 | Cohen et al. 200631 |
| Abatacept | 50.0a | 20.0a | 10.0a | Genovese et al. 200532 | 50.0 | 20.0 | 10.0 | Genovese et al. 200532 |
| TNF-IR Patients | ||||||||
| Tofacitinib | 51.0 | 37.0 | 16.0 | Burmester et al. 201316 | ||||
| Adalimumab | 48.2 | 21.2 | 6.8 | Degraded data from Keystone et al. 200424 | ||||
| Rituximab | 51.0 | 27.0 | 12.0 | Cohen et al. 200631 | ||||
| Abatacept | 50.0 | 20.0 | 10.0 | Genovese et al. 200532 | ||||
Note: Response was dependent on whether the therapy was administered with methotrexate (monotherapy or combination therapy) and whether the therapy was given to patients who had an inadequate response to methotrexate or to first-line bDMARD.
aThere were no monotherapy data available for abatacept, so it was assumed that the rates were equivalent to that of combination therapy.
ACR = American College of Rheumatology; bDMARD = biologic disease-modifying antirheumatic drug; MTX-IR = methotrexate inadequate responder; N/A = not available; TNF-IR = tumor necrosis factor inhibitor inadequate responder.